Drug Discovery World

JULY 1, 2024

. “Pharma represents one of the biggest industries in the world, and there is immense potential to make the drug development process more efficient. ” Advancements in AI are creating more candidate drugs than the industry can progress.

Pharma Companies 147

Pharma Companies Licensing Licensing Drugs 147

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. Financing When it comes to looking to the future in the drug discovery industry, an important question to ask is: Where is the money?

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

OCTOBER 11, 2023

Boehringer Ingelheim and CDR-Life entered a licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate in September 2021.

Clinical Trials 130

Clinical Trials Treatment Trials FDA Approval 130

Drug Discovery World

MARCH 13, 2024

Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor. at 16 weeks and 76.2% at 52 weeks). .”

Trials 130

Trials Clinical Trials Treatment Licensing 130

Drug Discovery World

AUGUST 9, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR T cell therapy.

Clinical Trials 130

Clinical Trials Trials Therapies Licensing 130

Drug Discovery World

AUGUST 2, 2022

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma. . Official comments . survival of ?less less than one year.

Trials 130

Trials FDA Immune Response Clinical Trials 130

Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . The trial will enrol up to 6,000 participants aged five years and older and will be conducted across 50 sites where Lyme disease is highly endemic. Official comments . “We

Vaccine 130

Vaccine Disease Trials Pharmaceutical Companies 130

Drug Discovery World

MARCH 24, 2023

This synergy was demonstrated by the AIPAC Phase IIb trial’s encouraging efficacy and safety, including a over 2.9-month Regulatory approval The company and the US Food and Drug Administration (FDA) agreed to the integrated Phase II/III trial design for AIPAC-003 that will help inform a Biologics License Application (BLA).

Trials 130

Trials Immune Response FDA Clinical Development 130

Drug Discovery World

FEBRUARY 1, 2023

Big pharma is helping to shape the focus The good news is that clinical trials are on the increase and market education is upping pace. Nothing is definitive yet, and these are complicated trials, but the world wants to move to safer alternatives that don’t impede daily life or cause further issues.

Clinical Trials 130

Clinical Trials Trials Pharmaceutical Companies Doctors 130

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

Drug Discovery World

AUGUST 25, 2023

The headline news this week reflects the high level of interest and investment in neuroscience drug discovery, particularly neurodegenerative diseases like Alzheimer’s; including positive clinical trial results for new immunotherapy and biotherapeutic candidates, and hopes that existing medications could slow the progression of dementia.

Clinical Trials 130

Clinical Trials Vaccine Licensing Licensing 130

Conversations in Drug Development Trends

OCTOBER 26, 2022

Bringing a psychedelic into a clinical trial setting is complex and requires a thorough operational approach to ensure the study’s success. Psychedelic trials need to be done with scientific rigor. Our team published recently in The Journal of Psychedelic Psychiatry exploring how we can bring more rigor to these trials.

Trials 97

Trials Clinical Trials Licensing Licensing 97

Conversations in Drug Development Trends

AUGUST 9, 2024

Authors: Matt Cooper, PhD, Executive Director, Therapeutic Strategy Lead, Oncology; Megan Morrison, Vice President, Asia Pacific Strategy Lead Adaptive trial designs have become essential in oncology, offering a flexible and efficient approach for conducting clinical trials.

Trials 80

Trials Clinical Trials Regulations FDA 80

Drug Discovery World

MARCH 20, 2024

Cancer Research UK and the Norwegian Cancer Society (NCS) have announced a new multi-project strategic partnership to maximise the unique drug development capabilities of both countries. Suitable projects will then be brought into the CDD post-approval for its experienced team to plan, sponsor and run an early-phase clinical trial.

Drugs 130

Drugs Clinical Trials Licensing Licensing 130

Drug Discovery World

JANUARY 15, 2024

Amgen and NVIDIA Amgen has announced plans to advance drug discovery using NVIDIA’s DGX SuperPOD-powered insights from human datasets. Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth.

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

Drug Discovery World

AUGUST 21, 2024

Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Drug Discovery World

MARCH 6, 2024

UK-based biotech SynaptixBio has secured a second Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA). Earlier last year the biotech successfully led a second round of investment, taking the total up to £13.2m ($16.7m), which will take it up to the start of in-human clinical trials later this year.

Disease 130

Disease FDA Therapies Drugs 130

Drug Discovery World

JULY 11, 2023

A first programme, BMS-986419 or EVT8683, targeting eIF2b, was in-licensed by BMS in September 2021, following the successful filing of an IND application with the FDA and has proceeded into clinical Phase I trials. The post Evotec and BMS enter drug discovery licence agreement appeared first on Drug Discovery World (DDW).

Licensing 189

Licensing Licensing Drugs Disease 189

Drug Discovery World

JULY 28, 2023

The top stories: Partnership could enhance antibody discovery for cancer research Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. The post This week in drug discovery (24-28 July) appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

Drug Discovery World

AUGUST 1, 2023

Synthetic biology is increasingly important to drug discovery and development. Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. In return MaxCyte will receive platform licensing fees and program-related revenue.

Drugs 130

Drugs Licensing Licensing Engineering 130

Drug Discovery World

JULY 12, 2024

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Asklepios BioPharmaceutical’s (AskBio) AB-1005 which is being developed for moderate Parkinson’s disease. AB-1005 is an investigational adeno-associated virus 2 glial cell line-derived neurotrophic factor (AAV2-GDNF) neurorestorative gene therapy.

Therapies 147

Therapies Clinical Trials FDA Clinical Development 147

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong. expressing cancers.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Discovery World

JULY 2, 2024

In a Phase I trial, patients with metastatic kidney cancer who took a live biotherapeutic product alongside immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes.

Trials 147

Trials Treatment Clinical Trials Licensing 147

Drug Discovery World

NOVEMBER 16, 2023

Casgevy (exagamglogene autotemcel, or exa-cel) is the first medicine to be licensed that uses gene editing tool CRISPR, for which its inventors were awarded the Nobel Prize in 2020. Trial results for Casgevy The authorisation is based on positive clinical trial data.

Therapies 277

Therapies Clinical Trials Trials Treatment 277

Drug Discovery World

JULY 2, 2024

This article will examine the regional focus of the country’s life sciences industry, its infrastructure of bioparks, and how this foundation ensures Switzerland maintains its role as a global leader in drug discovery. Switzerland, however, boasts three (or arguably, four) separate yet complimentary centres of life science innovation.

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Discovery World

FEBRUARY 27, 2023

Destiny Pharma is obliged to continue its current plan to complete the ongoing manufacture of all clinical trial supplies needed to undertake the required clinical studies. The post Companies agree up to $570m deal for C difficile drug appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

Drug Discovery World

MAY 6, 2024

In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. billion on R&D during 2021, with Germany and Switzerland being the biggest contributors, and around one fourth of clinical trials worldwide were performed in Europe 1.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

The Pharma Data

MARCH 31, 2023

AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. i for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive and consists of an anti-Claudin 18.2

Licensing 40

Licensing Licensing Small Molecule Drugs 40

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders.

Licensing 52

Licensing Licensing Disease Small Molecule 52

Drug Discovery World

AUGUST 24, 2022

The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment. As a community-based trial, participants will take the treatment or placebo in their own homes. The trial looks to include at least 500 participants in the UK. .

Research 246

Research Clinical Trials Virus Trials 246

BioPharma Drive: Drug Pricing

AUGUST 20, 2024

In addition to new stock offerings, this week saw Merck license an antibody drug conjugate and BARDA further work trying to innovate remote clinical trials.

Clinical Trials 57

Clinical Trials Licensing Licensing Trials 57

Drug Discovery World

APRIL 5, 2023

A new, oral, first-in-class experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows. It also supports the drug’s potential to treat other cancers. We hope that our drug goes on to show effectiveness in clinical trials.”

Clinical Trials 130

Clinical Trials Pharmacokinetics Drugs DNA 130

Drug Discovery World

DECEMBER 14, 2023

Dr Amrolia is Professor of Transplantation Immunology at the UCL Great Ormond Street Institute of Child Health and an international leader in CAR T-cell therapy for paediatric ALL, and ViroCell Biologics is a specialist viral vector CDMO for cell and gene therapy (CGT) clinical trials. The study is expected to initiate in Q2 2024.

Research 130

Research Clinical Trials Licensing Licensing 130

Drug Discovery World

JANUARY 3, 2024

It has been licensed by the National Medical Products Administration (NMPA) in cases where the infection is resistant to treatment with ganciclovir, valganciclovir, cidofovir or foscarnet. The post China’s NMPA okays maribavir for post-transplant cytomegalovirus appeared first on Drug Discovery World (DDW).

Licensing 130

Licensing Licensing Trials Therapies 130

Drug Discovery World

JANUARY 8, 2024

The partners plan to take a MERS vaccine from early development through Phase II clinical trials. If the Phase II clinical trials are successful, an investigational ready reserve of 100,000 doses will be developed to quickly enter clinical trials in the event of a substantial outbreak.

Vaccine 147

Vaccine Clinical Trials Licensing Licensing 147

DrugBank

AUGUST 15, 2024

Drug development is challenging, including not only the complexities of biomolecular drug mechanisms but also the convolutions of regulatory pathways and commercialization strategies. This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks.

Drug Development 82

Drug Development Clinical Trials Drugs Therapies 82

Drug Discovery World

MARCH 7, 2024

The merged pipeline features an antibody-drug conjugate (ADC) toolkit with novel payload and linker technologies. The programme was licensed from Bayer Healthcare and is a fifth generation neutrophil elastase inhibitor (NEI) targeting the inflammatory aspects of AATD, a rare condition.

Clinical Trials 147

Clinical Trials Licensing Licensing Clinical Development 147